Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Crism Thera (CRTX) Share Price

Price 13.00p on 03-02-2026 at 19:40:05
Change 0.50p 4%
Buy 13.50p
Sell 12.50p
Last Trade: Unknown 92,500.00 at 13.00p
Day's Volume: 498,857
Last Close: 13.00p
Open: 12.50p
ISIN: VGG042401262
Day's Range 12.50p - 13.00p
52wk Range: 6.25p - 29.00p
Market Capitalisation: £6.73m
VWAP: 12.97436p
Shares in Issue: 51.74m

Crism Thera (CRTX) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Unknown* 92,500 13.00p Negotiated Trade
16:42:15 - 03-Feb-26
Buy* 11,832 13.10p Ordinary
16:19:34 - 03-Feb-26
Sell* 1,395 12.75p Ordinary
15:57:11 - 03-Feb-26
Sell* 6,631 12.75p Ordinary
15:54:33 - 03-Feb-26
Unknown* 11,000 13.00p Ordinary
15:34:14 - 03-Feb-26
Sell* 27,834 12.75p Ordinary
15:06:12 - 03-Feb-26
Buy* 148 13.50p Ordinary
14:58:57 - 03-Feb-26
Buy* 3 13.50p Ordinary
14:34:49 - 03-Feb-26
Buy* 7,633 13.10p Ordinary
14:09:49 - 03-Feb-26
Buy* 3,333 13.50p Ordinary
13:18:25 - 03-Feb-26
See more Crism Thera trades

Crism Thera (CRTX) Share Price History

Time period:
to
Date Open High Low Close Volume
3rd Feb 2026 (Tue) 12.50 13.00 12.50 13.00 498,857
2nd Feb 2026 (Mon) 10.25 13.50 11.00 12.50 1,566,789
30th Jan 2026 (Fri) 10.25 10.25 10.25 10.25 369,252
29th Jan 2026 (Thu) 10.25 10.25 10.25 10.25 202,278
28th Jan 2026 (Wed) 10.25 10.25 10.25 10.25 21,714
27th Jan 2026 (Tue) 10.25 10.25 10.25 10.25 685,275
26th Jan 2026 (Mon) 10.25 10.25 10.25 10.25 283,811
23rd Jan 2026 (Fri) 10.25 10.25 10.25 10.25 66,297
22nd Jan 2026 (Thu) 10.25 10.25 10.25 10.25 238,481
21st Jan 2026 (Wed) 10.25 10.25 10.25 10.25 106,205
20th Jan 2026 (Tue) 10.25 10.25 10.25 10.25 183,396
19th Jan 2026 (Mon) 10.00 10.00 10.00 10.00 764,315
16th Jan 2026 (Fri) 9.75 10.00 9.75 10.00 652,836
15th Jan 2026 (Thu) 10.50 10.50 9.75 9.75 45,233
14th Jan 2026 (Wed) 10.50 10.50 10.50 10.50 12,065
13th Jan 2026 (Tue) 10.50 10.50 10.50 10.50 325,105
12th Jan 2026 (Mon) 10.75 10.75 10.50 10.50 39,925
9th Jan 2026 (Fri) 10.75 10.75 10.75 10.75 34,587
8th Jan 2026 (Thu) 10.75 10.75 10.75 10.75 96,316
7th Jan 2026 (Wed) 10.75 10.75 10.75 10.75 8,982
6th Jan 2026 (Tue) 10.75 10.75 10.75 10.75 81,074
5th Jan 2026 (Mon) 10.00 10.75 10.00 10.75 362,127
See more Crism Thera price history

Crism Thera (CRTX) Regulatory News

Date Source Headline
20th Jan 2026 7:00 am RNS Japanese Patent Grant
9th Jan 2026 7:00 am RNS Results of Shareholder Analysis
15th Dec 2025 2:29 pm RNS Result of Retail Offer
10th Dec 2025 7:25 am RNS Retail Offer
10th Dec 2025 7:00 am RNS Placing of £1,000,000
27th Nov 2025 7:00 am RNS Holding(s) in Company
30th Oct 2025 7:00 am RNS US Orphan Drug Designation Application
14th Oct 2025 7:00 am RNS Positive Preclinical Data in Prostate Cancer
15th Sep 2025 7:00 am RNS Half Year Report
12th Sep 2025 7:00 am RNS Notice of Interim Results and IMC Presentation
See more Crism Thera regulatory news

Crism Thera (CRTX) Share News

TRADING UPDATES: Netcall acquires Jadu for up to GBP19 million

10th Dec 2025 16:16

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More

CRISM reports "significant" preclinical data for prostate cancer drug

14th Oct 2025 16:50

(Alliance News) - CRISM Therapeutics Corp said on Tuesday that preclinical studies show that its ChemoSeed drug delivery platform could "could substantially enhance" the efficacy of docetaxel in the treatment of prostate cancer. Read More

EARNINGS: CRISM loss widens as "actively" prepares for phase 2 trial

15th Sep 2025 21:41

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: CRISM confident in ChemoSeed as targets trial approval

26th Aug 2025 13:56

CRISM Therapeutics Corp - British Virgin Islands-based pharmaceutical firm - As the firm held its annual general meeting, Chair Nermeen Varawalla says the firm must attract, retain and incentivise the best people as it continues to seek further validation for its novel delivery method. "[We] are confident that ChemoSeed has the potential to transform treatment for patients with solid-tumour cancers," Chair Varawalla continues. ChemoSeed is an implantable biodegradable drug delivery technology designed for the sustained delivery of chemotherapy directly into cancer tissue. Chair Varawalla says the company is focused on gaining trial approval from the UK Medicines & Healthcare products Regulatory Agency in glioblastoma and progressing towards dosing first patients in early 2026. Read More

UK shareholder meetings calendar - next 7 days

19th Aug 2025 14:58

Read More

See more Crism Thera news
FTSE 100 Latest
Value10,314.59
Change-26.97

Login to your account

Forgot Password?

Not Registered